Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Código QR

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Guardado en:

Detalles Bibliográficos
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/98b49330b88e4cb3a30a40500467de37
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Erika Richtig, et al.
Publicado: (2021)

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
por: Megumi Kai, et al.
Publicado: (2021)

Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
por: Avani M. Kolla BPhil, et al.
Publicado: (2021)

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Publicado: (2021)

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
por: Francesco Cognetti, et al.
Publicado: (2021)

Real-Time PCR Assay for the Detection and Quantification of Roe Deer to Detect Food Adulteration—Interlaboratory Validation Involving Laboratories in Austria, Germany, and Switzerland
por: Barbara Druml, et al.
Publicado: (2021)

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
por: Ayşe Hilal Eroğlu Küçükdiler, et al.
Publicado: (2021)

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
por: Thomas Grinda, et al.
Publicado: (2021)

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
por: Omid Hamid, et al.
Publicado: (2021)

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
por: Yifei Qin, et al.
Publicado: (2021)

Ferroptosis-Associated Classifier and Indicator for Prognostic Prediction in Cutaneous Melanoma
por: Hao Zeng, et al.
Publicado: (2021)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Sandip Ganguly, et al.
Publicado: (2021)

BAP1 methylation: a prognostic marker of uveal melanoma metastasis
por: Mathieu F. Bakhoum, et al.
Publicado: (2021)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Sanju Cyriac, et al.
Publicado: (2021)

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
por: C. B. Westphalen, et al.
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Frank Riemer, et al.
Publicado: (2021)

Correction: In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
Publicado: (2021)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Shebli Atrash, et al.
Publicado: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Alexander N Shoushtari, et al.
Publicado: (2021)

Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma
por: Melanie Boxberg, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Thomas F Gajewski, et al.
Publicado: (2021)

Melanoma de mucosa oral
por: Gustavo Nader Marta, et al.
Publicado: (2007)

Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
por: Richard Carvajal, et al.
Publicado: (2021)

Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations
por: S. Vasudevan, et al.
Publicado: (2021)

Prognostic Factor Utility of BAP1 Immunohistochemistry in Uveal Melanoma: A Single Center Study in Spain
por: Laura Tabuenca Del Barrio, et al.
Publicado: (2021)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: William L Redmond, et al.
Publicado: (2021)

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
por: Michael B. Atkins, et al.
Publicado: (2021)

Radiotherapy in the Treatment of Subcutaneous Melanoma
por: Valentina Borzillo, et al.
Publicado: (2021)

Pembrolizumab-induced massive hypereosinophilia associated with mononeuritis multiplex, brain microvascular lesions and intestinal eosinophilic infiltration in a melanoma patient
por: Kim Dao, et al.
Publicado: (2021)

Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria
por: Gennadi Tulchiner, et al.
Publicado: (2021)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Shahneen Sandhu, et al.
Publicado: (2021)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Naoya Maekawa, et al.
Publicado: (2021)

Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy
por: Sabino Strippoli, et al.
Publicado: (2021)

Nomogram based on autophagy related genes for predicting the survival in melanoma
por: Guangtong Deng, et al.
Publicado: (2021)

Sparse Regression in Cancer Genomics: Comparing Variable Selection and Predictions in Real World Data
por: Robert J O’Shea, et al.
Publicado: (2021)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Weiping Liu, et al.
Publicado: (2021)

Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy
por: Alberto Carmona-Bayonas, et al.
Publicado: (2021)

Quality of Life Among Breast Cancer Patients Attending Hawassa University Comprehensive Specialized Hospital Cancer Treatment Center
por: Koboto DD, et al.
Publicado: (2020)

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects
por: Na Li, et al.
Publicado: (2021)